Cargando…
From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris
BACKGROUND: Expansion of the genetic code is a frequently employed approach for the modification of recombinant protein properties. It involves reassignment of a codon to another, e.g., unnatural, amino acid and requires the action of a pair of orthogonal tRNA and aminoacyl tRNA synthetase modified...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367057/ https://www.ncbi.nlm.nih.gov/pubmed/35953849 http://dx.doi.org/10.1186/s12934-022-01882-6 |
_version_ | 1784765705093120000 |
---|---|
author | Tir, Nora Heistinger, Lina Grünwald-Gruber, Clemens Jakob, Leo A. Dickgiesser, Stephan Rasche, Nicolas Mattanovich, Diethard |
author_facet | Tir, Nora Heistinger, Lina Grünwald-Gruber, Clemens Jakob, Leo A. Dickgiesser, Stephan Rasche, Nicolas Mattanovich, Diethard |
author_sort | Tir, Nora |
collection | PubMed |
description | BACKGROUND: Expansion of the genetic code is a frequently employed approach for the modification of recombinant protein properties. It involves reassignment of a codon to another, e.g., unnatural, amino acid and requires the action of a pair of orthogonal tRNA and aminoacyl tRNA synthetase modified to recognize only the desired amino acid. This approach was applied for the production of trastuzumab IgG carrying p-azido-l-phenylalanine (pAzF) in the industrial yeast Pichia pastoris. Combining the knowledge of protein folding and secretion with bioreactor cultivations, the aim of the work was to make the production of monoclonal antibodies with an expanded genetic code cost-effective on a laboratory scale. RESULTS: Co-translational transport of proteins into the endoplasmic reticulum through secretion signal prepeptide change and overexpression of lumenal chaperones Kar2p and Lhs1p improved the production of trastuzumab IgG and its Fab fragment with incorporated pAzF. In the case of Fab, a knockout of vacuolar targeting for protein degradation further increased protein yield. Fed-batch bioreactor cultivations of engineered P. pastoris strains increased IgG and IgG(pAzF) productivity by around 50- and 20-fold compared to screenings, yielding up to 238 mg L(−1) and 15 mg L(−1) of fully assembled tetrameric protein, respectively. Successful site-specific incorporation of pAzF was confirmed by mass spectrometry. CONCLUSIONS: Pichia pastoris was successfully employed for cost-effective laboratory-scale production of a monoclonal antibody with an unnatural amino acid. Applying the results of this work in glycoengineered strains, and taking further steps in process development opens great possibilities for utilizing P. pastoris in the development of antibodies for subsequent conjugations with, e.g., bioactive payloads. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-022-01882-6. |
format | Online Article Text |
id | pubmed-9367057 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93670572022-08-12 From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris Tir, Nora Heistinger, Lina Grünwald-Gruber, Clemens Jakob, Leo A. Dickgiesser, Stephan Rasche, Nicolas Mattanovich, Diethard Microb Cell Fact Research BACKGROUND: Expansion of the genetic code is a frequently employed approach for the modification of recombinant protein properties. It involves reassignment of a codon to another, e.g., unnatural, amino acid and requires the action of a pair of orthogonal tRNA and aminoacyl tRNA synthetase modified to recognize only the desired amino acid. This approach was applied for the production of trastuzumab IgG carrying p-azido-l-phenylalanine (pAzF) in the industrial yeast Pichia pastoris. Combining the knowledge of protein folding and secretion with bioreactor cultivations, the aim of the work was to make the production of monoclonal antibodies with an expanded genetic code cost-effective on a laboratory scale. RESULTS: Co-translational transport of proteins into the endoplasmic reticulum through secretion signal prepeptide change and overexpression of lumenal chaperones Kar2p and Lhs1p improved the production of trastuzumab IgG and its Fab fragment with incorporated pAzF. In the case of Fab, a knockout of vacuolar targeting for protein degradation further increased protein yield. Fed-batch bioreactor cultivations of engineered P. pastoris strains increased IgG and IgG(pAzF) productivity by around 50- and 20-fold compared to screenings, yielding up to 238 mg L(−1) and 15 mg L(−1) of fully assembled tetrameric protein, respectively. Successful site-specific incorporation of pAzF was confirmed by mass spectrometry. CONCLUSIONS: Pichia pastoris was successfully employed for cost-effective laboratory-scale production of a monoclonal antibody with an unnatural amino acid. Applying the results of this work in glycoengineered strains, and taking further steps in process development opens great possibilities for utilizing P. pastoris in the development of antibodies for subsequent conjugations with, e.g., bioactive payloads. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-022-01882-6. BioMed Central 2022-08-11 /pmc/articles/PMC9367057/ /pubmed/35953849 http://dx.doi.org/10.1186/s12934-022-01882-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Tir, Nora Heistinger, Lina Grünwald-Gruber, Clemens Jakob, Leo A. Dickgiesser, Stephan Rasche, Nicolas Mattanovich, Diethard From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris |
title | From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris |
title_full | From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris |
title_fullStr | From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris |
title_full_unstemmed | From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris |
title_short | From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris |
title_sort | from strain engineering to process development: monoclonal antibody production with an unnatural amino acid in pichia pastoris |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367057/ https://www.ncbi.nlm.nih.gov/pubmed/35953849 http://dx.doi.org/10.1186/s12934-022-01882-6 |
work_keys_str_mv | AT tirnora fromstrainengineeringtoprocessdevelopmentmonoclonalantibodyproductionwithanunnaturalaminoacidinpichiapastoris AT heistingerlina fromstrainengineeringtoprocessdevelopmentmonoclonalantibodyproductionwithanunnaturalaminoacidinpichiapastoris AT grunwaldgruberclemens fromstrainengineeringtoprocessdevelopmentmonoclonalantibodyproductionwithanunnaturalaminoacidinpichiapastoris AT jakobleoa fromstrainengineeringtoprocessdevelopmentmonoclonalantibodyproductionwithanunnaturalaminoacidinpichiapastoris AT dickgiesserstephan fromstrainengineeringtoprocessdevelopmentmonoclonalantibodyproductionwithanunnaturalaminoacidinpichiapastoris AT raschenicolas fromstrainengineeringtoprocessdevelopmentmonoclonalantibodyproductionwithanunnaturalaminoacidinpichiapastoris AT mattanovichdiethard fromstrainengineeringtoprocessdevelopmentmonoclonalantibodyproductionwithanunnaturalaminoacidinpichiapastoris |